小分子
化学生物学
生物
药物开发
化学
细胞生物学
肽
结构生物学
药理学
作者
Shenxin Zeng,Hongjie Zhang,Zhengrong Shen,Wenhai Huang
标识
DOI:10.3389/fchem.2021.639176
摘要
Photopharmacology is an emerging field that uses light to precisely control drug activity. This strategy promises to improve drug specificity for reducing off-target effects. Proteolysis-targeting chimeras (PROTACs) are an advanced technology engineered to degrade pathogenic proteins through the ubiquitin-proteasome system for disease treatment. This approach has the potential to target the undruggable proteome via event-driven pharmacology. Recently, the combination strategy of photopharmacology and PROTACs has gained tremendous momentum for its use in the discovery and development of new therapies. This review systematically focuses on PROTAC-based photopharmacology. Herein, we provide an overview of the new and vibrant research on photoPROTACs, discuss the advantages and disadvantages of this approach as a biological tool, and outline the challenges it faces in a clinical setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI